Trichome Extracts / Canna Pacific

In May 2026, Vapor Pens accounted for 57.06% share with 93.77% year-over-year growth but a 12.30% month-over-month decline, while Flower held 27.35% share with a 7.43% year-over-year contraction but a 13.97% month-over-month increase; this split contrasts with Pre-Roll at 8.82% share posting a 28.14% year-over-year decline and a 1.65% month-over-month dip, and Concentrates at 6.77% share with a 10.34% year-over-year decline and a 0.42% month-over-month uptick. Average price rose 9.07% year-over-year to $20.85 as Vapor Pens averaged $24.42 and Flower $22.47, implying mix-driven pricing support alongside volume shifts. Taken together, the surge in Vapor Pens year-over-year alongside Flower’s month-over-month rebound suggests a pivot from a single-engine category to a two-category base, implying that the brand’s overall 26.88% year-over-year sales lift is increasingly dependent on balancing Vapor Pens’ scale with Flower’s short-cycle momentum.

The category rotation repositions Trichome Extracts / Canna Pacific toward higher-ticket inhalables while cushioning volatility: Vapor Pens’ 12.30% month-over-month dip against a 93.77% year-over-year rise, paired with Flower’s 13.97% month-over-month gain amid a 7.43% year-over-year decline, indicates demand hedging between discretionary vape purchases and replenishment-oriented Flower. With Pre-Roll shrinking 28.14% year-over-year and Concentrates down 10.34% year-over-year but flat month-over-month at 0.42%, the tail categories are unlikely to drive near-term share gains; instead, the current mix and a rank of 26 in Washington Vapor Pens argue for defending pen share while using Flower’s month-over-month traction to stabilize sell-through, implying a positioning that prioritizes price-tier breadth in Vapor Pens and basket-building via Flower to preserve the brand’s 57.06%/27.35% core mix.